CN Bio services

Employing our Liver-on-a-chip hepatic co-culture model (evaluated by our collaborators at the U.S. FDA), our DILI in vitro Service can screen your small molecules, antibodies, ASO, and gene editing reagents to establish human DILI risk.

Our Non-Alcoholic Fatty Liver Disorder (NAFLD)/NASH in vitro Services offer a preclinical tool to test therapeutics in a human-relevant model, replicating key disease phenotypes including fibrosis and reporting clinical biomarkers to allow translatability to clinical trials.